Clinical decision support that reasons like an endocannabinoid physician: map the CB1, CB2 and endogenous-ligand system, weigh the clinical endocannabinoid deficiency hypothesis honestly, modulate tone with lifestyle first, and target a cannabinoid by its receptor — with the decision rule and exactly what would change it. Built for verified physicians.
Two real endocannabinoid-medicine questions, each reasoned the way HeyHippocrates answers: the skills fire, the answer is cited, the decision rule is explicit, and what's missing is flagged. Scroll to each.
Migraine, fibromyalgia and irritable bowel overlapping in one patient, poorly responsive to standard therapy — the endocannabinoid lens?
These three conditions cluster together and share features attributed to a proposed clinical endocannabinoid deficiency — a hypothesized low endocannabinoid tone. Treat it as a lens, not a proven diagnosis: first exclude and optimize the standard treatable causes of each condition, then modulate the endocannabinoid system, beginning with lifestyle that raises tone — regular aerobic exercise, sleep, stress reduction and omega-3 precursors. Consider cannabinoid therapy only as an evidence-bounded adjunct, and say plainly what remains unproven.
Decision ruleMigraine + fibromyalgia + IBS overlap → consider the clinical endocannabinoid deficiency lens (a hypothesis, not proven); exclude and optimize standard causes first; modulate tone with lifestyle (aerobic exercise, sleep, stress, omega-3); cannabinoid therapy only as an evidence-bounded adjunct.
Not established from this alone — the standard workup, the evidence and the response change whether the lens helps.
How do I reason about which cannabinoid or ECS modulator fits a given symptom?
Map the target to the mechanism. CB1 receptors are central and drive analgesia, antinausea and appetite, but also the psychoactivity, tolerance and cognitive effects of THC. CB2 receptors are peripheral and immune, offering anti-inflammatory effects with little psychoactivity. CBD is not a direct CB1 agonist — it acts on TRPV1 and 5-HT1A and raises anandamide by inhibiting its breakdown. Match the receptor to the goal, start low and titrate for the biphasic dose-response, and account for the entourage effect of the whole-plant matrix.
Decision ruleCB1 (central: analgesia/antinausea/appetite, but psychoactivity/tolerance) vs CB2 (peripheral/immune: anti-inflammatory, low psychoactivity) vs CBD (non-CB1; TRPV1/5-HT1A + raises anandamide); match receptor to goal; start low, titrate for the biphasic response; account for the entourage effect.
Not established from this alone — the target symptom, the receptor profile and the dose change the choice.
Illustrative simulations. The physician always decides.
The exact questions your field searches for — answered in the format the knowledge base speaks: the answer, the decision rule, what's missing, and the source.
The endocannabinoid system is a widespread signaling network of two main receptors — CB1, mostly central and neuronal, and CB2, mostly peripheral and immune — the endogenous ligands anandamide and 2-arachidonoylglycerol, and the enzymes that make and break them, chiefly FAAH and MAGL. It works largely as a retrograde, on-demand brake that tunes pain, mood, appetite, sleep, immune activity and neuroprotection toward homeostasis. Its breadth is why modulating it touches so many systems — and why effects are dose-dependent and context-dependent.ECS physiology
Decision ruleECS = CB1 (central) + CB2 (peripheral/immune) + ligands (anandamide, 2-AG) + enzymes (FAAH, MAGL); a retrograde, on-demand homeostatic system tuning pain/mood/appetite/sleep/immunity; effects dose- and context-dependent.
Missing data: the target tissue, the receptor and the dose change the clinical effect.
Clinical endocannabinoid deficiency is a hypothesis that a low endocannabinoid tone underlies a cluster of conditions — migraine, fibromyalgia and irritable bowel syndrome most cited — which overlap clinically and are often refractory. It is biologically plausible and generates useful treatment ideas, but it is not an established, measurable diagnosis. Use it as a reasoning lens, not a label: exclude the standard causes, optimize the standard treatments, and consider system-directed measures where the evidence supports them, being explicit about what is unproven.CED hypothesis
Decision ruleCED = hypothesis (low endocannabinoid tone) linking migraine/fibromyalgia/IBS; plausible, generates ideas, but not a measurable diagnosis; use as a lens, not a label; exclude and treat standard causes first; be explicit about the evidence gap.
Missing data: the standard workup and the evidence base change how far the hypothesis takes you.
Yes — several lifestyle levers modulate the endocannabinoid system. Moderate aerobic exercise raises circulating anandamide and contributes to the sense of well-being once attributed to endorphins. Adequate sleep, stress reduction and mind-body practice shift endocannabinoid signaling favorably, and dietary omega-3 fatty acids supply the precursors for endocannabinoid synthesis. These carry little downside and are the sensible first move before any cannabinoid, especially where the evidence for drug therapy is thin.lifestyle & the ECS
Decision ruleRaise or modulate tone non-pharmacologically: aerobic exercise (raises anandamide), sleep, stress reduction and mind-body, dietary omega-3 precursors; low-risk first-line before cannabinoids, especially where drug evidence is limited.
Missing data: the baseline habits, the comorbidity and the goal change which levers help most.
THC is a partial agonist at CB1 and CB2; its CB1 action gives analgesia, antiemesis and appetite stimulation but also the psychoactivity, tolerance and cognitive and cardiovascular effects. CBD is not a direct CB1 agonist — it modulates TRPV1 and 5-HT1A, dampens THC psychoactivity, and raises anandamide by inhibiting FAAH. Responses are biphasic, so low and high doses can differ in direction, and the whole-plant entourage effect of minor cannabinoids and terpenes may modify the result. Start low, go slow, and watch for drug interactions through CYP metabolism.cannabinoid pharmacology
Decision ruleTHC = CB1/CB2 partial agonist (analgesia/antiemesis/appetite + psychoactivity/tolerance); CBD = non-CB1 (TRPV1/5-HT1A, raises anandamide, dampens THC); biphasic dosing; entourage effect; start low and go slow; watch CYP drug interactions.
Missing data: the cannabinoid, the dose and the concomitant drugs change the effect and the interactions.
Your whole practice, one specialist brain — grounded in champion-authored, cited knowledge.
A generalist endocannabinoid-medicine colleague across the ECS map, endocannabinoid tone, the deficiency hypothesis, non-drug modulation and cannabinoid pharmacology — cited, non-directive, always with the decision rule.
Deep specialist agents for the endocannabinoid system and tone, the deficiency hypothesis, non-drug modulation, and cannabinoid receptor pharmacology — each its own soul and knowledge base — plus your own uploaded materials.
From the receptor map to the honest limits of the hypothesis the margin is thin. Only one of these reasons like an endocannabinoid-medicine colleague whose every claim you can trace.
The waitlist is a founding cohort. Members shape the endocannabinoid medicine build, get in before anyone else, and lock the founding price for good.
Leave your name and work email. We'll reach out the moment endocannabinoid medicine opens — with your Founding Endocannabinoid Physician offer.
One email at launch. No spam, ever.
It reasons in the frameworks you use — the ECS map, the clinical endocannabinoid deficiency hypothesis, non-drug tone modulation and cannabinoid receptor pharmacology — and always shows the reasoning, the decision rule and what would change it, including what is unproven. The decision always stays your call.
Both. Residents use it to pressure-test a plan and learn the decision rule; attendings use it as a fast, cited second opinion in a still-emerging field. Access is gated to verified physicians.
The endocannabinoid system and tone, the deficiency hypothesis, non-drug modulation, and cannabinoid receptor pharmacology each have their own deep specialist agent on the Pro plan, on top of the full endocannabinoid-medicine scope on Basic.
No. It is physician-facing clinical decision support — a cited thinking partner. It does not diagnose, does not treat, and gives no patient-facing advice. The decision always stays with you.
Every answer is grounded only in champion-authored, cited endocannabinoid-medicine knowledge — traceable, not hallucinated — and always states the decision rule plus what data is missing, instead of a confident guess.
HeyHippocrates